Register for our free email digests:
Inspiration Biopharmaceuticals, Inc.
http://www.inspirationbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inspiration Biopharmaceuticals, Inc.
Transcatheter Systems Set To Dominate Heart Valve Market
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
Market Intel: Voyage Into Point-Of-Care Testing Gets Deeper
Diagnostic testing is increasingly moving from centralized laboratories into pharmacies, physicians' offices, hospitals and directly to consumers as part of the transition to value-based care with its focus on providing quality care at a lower cost. Point-of-care testing (POCT) – and what it means for the future of health-care delivery, health-care providers and creators of innovative technologies joining forces to satisfy consumers' growing appetite for convenient and rapid testing – took centerstage at the recent AACC Annual Meeting in San Diego. This feature takes a closer look at the increasing migration of POCT into the retail arena, specifically pharmacies, to support primary-care providers, along with its challenges. It also highlights emerging trends and technologies, including presentations of the "Star Trek-like" innovations from the Qualcomm Tricorder XPrize competition winners that are bound to disrupt the landscape of direct-to-consumer testing. We also provide expert opinions of the pros and cons of bringing POC services closer to consumers.
Aegerion CFO resigns
Aegerion Pharmaceuticals, a biopharmaceutical company developing innovative therapies for patients with rare diseases, has announced Mark Fitzpatrick, the company's chief financial officer, has resigned – effective 14 May 2015.
Ipsen goes back to black
French pharma company Ipsen has reported a return to profit in 2013 after putting behind it a costly venture in hemophilia which saw its partner Inspiration Biopharmaceuticals go bust and investigational candidate OBI-1 sold to Baxter International. Its outlook for 2014 was broadly welcomed by analysts as in line with expectations.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals